The Pharma Letter M&A roundup - February 2023

If January offered excitement, promise and hope for a busy year of pharma M&A ahead, then February has more than tempered those expectations.

There were no major acquisitions by pharma's big players during the month, with only a handful of deals announced at all. Perhaps the arrival of spring and the return of many of the major scientific congresses will bring a higher volume of acquisitions in March and April.

Our tables below show the activity over the month, how it compares to previous years and which big pharma companies are spending the most on replenishing their pipelines as 2023 goes on.